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Abstract: 
 
Purpose: The aim of the paper is to assess the choices made within the trade-offs specific for 
the commercialization of a biomedical product in the circumstances of a narrow window of 
opportunity. 
Design/methodology/Approach: The analysis of the literature on this subject revealed a 
research gap in the analysis of the trade-offs occurring during R&D works in the process of 
the development and commercialization of a biomedical product in the circumstances of a 
narrow window of opportunity for market introduction. For the sake of capturing the 
dynamic specificity of the innovation process and its comprehensive presentation, the 
authors decided to use the case study method. 
Findings: The results of the research suggest that focusing on one factor (time) is possible 
when mobilising the entire potential of the enterprise, but ultimately it does not have to 
translate into faster launch of serial production and taking advantage of the window of 
opportunity. Research shows that excessive simplifications in the area of innovation process 
management lead to the need to re-implement some stages of the R&D works. 
Practical Implications: Conclusions from the analysis of trade-offs can help managers in 
making key decisions within the innovative process under time pressure. 
Originality/Value: Despite the time pressure, it is advisable to follow the main principles of 
conducting the research process, in particular, defining milestones in advance, exercising 
critical approach to formulating assumptions, taking care of good communication between 
R&D discipline teams, making at least a preliminary trade-off calculation. 
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The SARS-CoV-2 coronavirus pandemic has rapidly changed the global socio-
economic situation (Grima et al., 2020; Khan et al., 2020). Governments are trying 
to counter the negative consequences of the COVID-19 pandemic by using two 
types of strategies, mitigation or suppression, or a combination of both. Regardless 
of the adopted strategy to deal with the pandemic, the basic approach is testing the 
population for the presence of the SARS-CoV-2 coronavirus. Testing addresses the 
question of the percentage of the population infected with the pathogen and is the 
key information determining further activities. However, the novelty of the pathogen 
created an urgent need to develop effective tests for SARS-CoV-2. Many companies 
have undertaken R&D activities to develop and produce a coronavirus test. 
 
A characteristic feature of the innovation process in question is a strong time 
pressure. There are two reasons for it. First, there is a race to save as many potential 
victims of the pathogen as possible. Testing is the basis of proper diagnosis and, 
subsequently, of the eligibility for vaccination. Secondly, according to the authors' 
knowledge, over 1000 companies have commenced R&D works regarding the 
commercialization of the SARS-CoV-2 test. This obviously has a positive effect on 
the search for and use of new solutions to beat the competition. And there is a lot at 
stake. By definition, a pandemic is of global nature. The development and 
implementation into serial production of a test providing accuracy, reliability, rapid 
diagnosis and low unit costs will determine the market position and financial results 
of the test manufacturer. 
 
As a result, innovative works are carried out with the narrow window of opportunity 
in mind. Such circumstances occur when the demand for the product grows rapidly 
and at the same time many competing companies take up the challenge of its 
development. In this situation, each company tries to implement solutions that will 
speed up R&D and production activities. A natural solution, commonly implemented 
in such situation, involves improvement in the area of management. However, 
organizational changes in the R&D process make it necessary to redefine the trade-
offs in terms of the test commercialization time, incorporated features/parameters 
(product functionality) and the costs of research. Giving priority to the time factor 
results in changes in the trade-offs between the above three factors. In the new 
circumstances, the question of the final effects of the commercialization process 
needs to be considered anew. 
 
The aim of the article is to assess the choices made within the trade-offs specific for 
the commercialization of a biomedical product in the circumstances of a narrow 
window of opportunity. The analysis of the literature on this subject revealed a 
research gap in the analysis of the trade-offs occurring during R&D works in the 
process of the development and commercialization of a biomedical product in the 
circumstances of a narrow window of opportunity for market introduction. For the 
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sake of capturing the dynamic specificity of the innovation process and its 
comprehensive presentation, the authors decided to use the case study method. 
 
2. Acceleration of the Innovation Process 
 
Innovation constitutes a mainstream interest of the technical, economic and social 
sciences (Acosta et al., 2016; Saunila, 2020). Novelty is the focal point of 
innovation. According to the guidelines of the "Oslo Manual", a novelty can 
manifest itself in the form of a product, a process within a given entity, marketing 
and organization of basic (production, service, commercial) as well as management 
processes, including the business model (Oslo Manual, 2018). 
 
The innovation process aims at effective commercialization of the innovation and its 
acceptance by the buyers/users. The innovation process takes place in several 
phases, starting with the creation of the appropriate potential in the organization, and 
ending with commercialization. Figure 1 shows a general scheme of creation and 
commercialization. 
 
Figure 1. General scheme of the innovation process 
 
 
Source: Frederiksen and Knudsen, 2017. 
 
Time-to-market is important for the effectiveness of commercialization. Going 
through all the phases of the innovation process to develop a solution that meets the 
assumptions takes time. On the other hand, there is an optimal time frame for 
introducing a given product to the market - the window of opportunity (Kim and 
Kang, 2019; Messica and Mehrez, 2002). If the commercialization comes too late, it 
may destroy the chances of success - competitors who released the product earlier 
have already acquired customers, buyers do not want to pay a premium price for 
another similar product, and finally, in the case of cyclical branches, the demand 
may quickly disappear. In the event of late market entry, there is a risk that the 




regulator might alter the requirements and another time-consuming prototype change 
will be necessary. 
 
On the other hand, releasing an innovation too quickly may involve offering buyers 
a product that is not fully developed and does not meet all their requirements despite 
the hype. It may also happen that the product does not meet the expectations of the 
customers at all due to its low quality or safety issues. In this respect, another risk is 
an over-proportional increase in innovative process expenditure, consisting in the 
allocation of additional personnel, new resources, etc., which, in turn, will hamper 
the economic profitability of the project. There is also a risk that the involvement of 
a significant part of the company personnel in a given project will result in the 
slowdown/abandonment of all other research and development activities that could, 
at least theoretically, result in the development of a more groundbreaking solution. 
The window of opportunity is relatively small when (Bayus, 1997): 
 
• Product lifetimes are short 
• The time to peak sales is small 
• Average product margins are sharply declining over time. 
 
The window of opportunity is created by three groups of factors: those related to 
scientific and technological progress (knowledge and technology), changes in 
demand, and guidelines and regulations of government agencies (Kim and Kang, 
2019). New opportunities for creating innovation appear in result of changes related 
to the level of knowledge and the possibility of using particular raw materials, 
materials, solutions or systems in a new, more efficient or unprecedented way. 
Examples include such industries as ICT, biotechnology and aviation. 
 
The group of factors related to demand strongly urges enterprises towards faster 
time-to-market. Today, more and more customers want their preferences to be met 
immediately. This aspect also involves rapidly changing fashions or trends, price 
pressure and shortening of the product life cycle. The demand for the products of a 
particular company is also related to the level of competition in a given sector. The 
panacea may be to launch products onto the market faster. In this perspective, 
innovation is one of the instruments of competition and maintaining a competitive 
advantage. 
 
The third group of factors are regulations and restrictions imposed by the authorities. 
A classic example is the automotive industry, which, due to growing environmental 
protection guidelines, has to develop new versions of engines with lower emissions 
of harmful gases. The aforementioned COVID-19 pandemic also brought about 
many regulatory changes, forcing companies to implement various types of 
innovation in terms of distribution, production methods, work organization, etc. 
Taking the above factors into account, it becomes natural to strive for the 
acceleration of the innovation process. However, the question is how to do this. The 
literature on the subject provides the following ways to boost efforts on the creation 
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and commercialization of innovations (Calantone and Benedetto, 2000; Cooper, 
2019; Parthasarthy and Hammond, 2002): 
 
• Formulating realistic assumptions across all phases of the innovation process, 
available resources, market information, etc. 
• Reducing product complexity – determination of a minimum set of 
functionalities on the basis of MVP concept (Minimum Viable Product) 
• Sharp, early, and fact-based product definition (Unique Selling Proposition) 
• Iterative, spiral development – build, test, feedback, and revise 
• Parallel and concurrent processing of innovation process phases 
• Involving (potential) users of a given solution in providing feedback and 
assessing their usefulness as soon as possible at every stage of the innovation 
process 
• Implementing agile management methods 
• Improving communication between R&D - production - marketing teams by 
defining the rules and using ICT tools 
• Increasing the motivation for creativity/performance of R&D - production - 
marketing teams by establishing a bonus scheme, incentive program, 
participation in ownership (shares) or decision making. 
• Implementing a participatory style of management 
• In economically justified cases, redundancy of human resources and other assets, 
including cooperation with other entities. 
 
The acceleration of the innovation process - although desirable - is associated with 
certain types of risk. When deciding to accelerate work on a new solution, it is 
necessary to perform a profit and loss calculation every time. In this context, the 
following trade-offs are enumerated (Bayus, 1997): 
 
• too early release of the product vs. unused opportunities 
• time-to-market vs. development cost 
• time-to-market vs. product features. 
 
The above-mentioned dilemmas create a space for making decisions regarding 
actions accelerating the commercialization of innovations. However, the right choice 
is not at all obvious during the process, due to incomplete information and the 
emotional commitment of the decision maker. 
 
3. Research Methods 
 
3.1 Research Gap 
 
A review of literature databases showed that the analysis of balancing various 
factors within specific trade-offs is a popular subject of scientific research on 
innovation. In particular, the studies focused on trade-offs within national systems of 




innovation, intellectual rights, mergers and acquisitions, and business models 
(Cohen et al., 1996; Kim, 2017; Roin, 2014; Weigelt and Sarkar, 2012). 
 
The above sources refer to all business activities and are not limited to a single 
industry. Taking biomedical products into account, a search of literature databases 
revealed few sources (Angus, 2020; Corso and Gastaldi, 2010; Ehlers, 2011; Hirch, 
2016). By applying an additional time pressure filter and taking advantage of the 
emerging window of opportunity, to the best of the authors' knowledge, only two 
papers deal with the trade-off of too fast versus too late market introduction. Corso 
and Castaldi (2010) analyzed the relationship between effective exploitation and 
flexible exploration as a result of the use of information and communication 
technologies in the healthcare sector. The authors based their analysis on empirical 
research. In turn, the work of Angus (2020) addressed the issues of optimizing the 
trade-off between learning time and commencing operation in the circumstances of 
the COVID-19 pandemic (Angus, 2020). The work subscribes to the mainstream of 
theoretical and postulative considerations. 
 
In view of the above, the authors identified a research gap in the analysis of the 
trade-offs occurring during R&D works in the process of the development and 
commercialization of a biomedical product in the circumstances of a narrow window 
of opportunity for market introduction. Such a situation occurs in the event of a 
pandemic. This is when the need to develop and launch life and health saving 
biomedical products as quickly as possible is clearly visible. However, in terms of 
the current competitive situation, shortening the time to commercialization appears 
to be a more universal objective after mobilizing the R&D process. However, 
shortening the time has various consequences for research and production that 
deserve further exploration. 
 
3.2 The Research Problem, the Purpose of the Study and the Research Method 
 
On the basis of the identified research gap, augmented by the current pandemic 
circumstances, the authors formulated the following research problem: how the 
imperative of shortening the time needed to create a test for the presence of SARS-
CoV-2 virus affected the course and effects of the product commercialization 
process in terms of the production launch time, costs and product features. The 
research problem relates to three typical trade-offs occurring in the course of 
research and development activities (Bayus, 1997): 
 
• Too early release of the product vs. unused opportunities, 
• Time-to-market vs. development cost, 
• Time-to-market vs. product features. 
 
The aim of the paper is to assess the choices made within the trade-offs specific for 
the commercialization of a biomedical product in the circumstances of a narrow 
window of opportunity. 
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Research questions that need to be asked to achieve the set aim of the work, and thus 
to explore and clarify the research problem are as follows: 
 
1. What are the reasons for shortening the time of effective commercialization of 
the SARS-CoV-2 test? 
2. What is the course of the commercialization process in the case of the SARS-
CoV-2 test compared to the commercialization of the influenza test in the 
business under investigation? 
3. What are the effects of the commercialization process in the case of the 
SARS-CoV-2 test compared to the commercialization of the influenza test in 
the business under investigation? 
4. What do the trade-offs encountered during the commercialization of the 
SARS-CoV-2 test look like? 
5. What are the effects of the choices made by the management of the business 
under investigation as part of trade-offs (time of production commencement, 
costs and product functions)? 
 
The case study method was used for the research purposes. The rationale for 
selecting such a method was to match the nature of the research problem. The 
idiographic approach facilitates capturing of the research problem in all its dynamic 
complexity, which is appropriate for this research area. The case study method 
facilitates: 
 
• Taking into account the context/specificity of a given organization and its 
environment (Coughlan and Coghlan, 2016) 
• Adopting a broad view of the constantly changing, dynamic processes (Corallo, 
2007) 
• Obtaining an in-depth answer to the questions "how", "what", "in what way" 
(Yin, 2017), which constitute the focus of this study. 
 
3.3 Research Techniques and Design 
 
The conducted analysis is based on the knowledge made available by the 
management of company under investigation (PF company) relating to the processes 
of developing tests that detect viruses or bacteria in the body. The article analyses 
the trade-offs taking place during the commercialization of the SARS-CoV-2 
coronavirus test. 
 
The research was conducted in December 2020 and January 2021. The research was 
conducted using semi-structured interview and participant observation contributed 
by one of the authors. The interlocutors were the PF company CEO and R&D 
manager. The applied method of selecting interlocutors was dictated by their 
knowledge of various aspects of R&D work performed when developing the SARS-
CoV-2 test. 




The interlocutors were interviewed three times - the answers from the previous stage 
were analyzed by the authors, and the acquired knowledge regarding the course and 
effects of the coronavirus test implementation was used to formulate additional, 
more detailed questions. The interview conducted in this way provided us with a 
fairly detailed insight into the company's activities and better understanding of the 
problem. 
 
4. The Conditions and the Process of Implementation and 
Commercialization of the SARS-CoV-2 Test 
 
Antigen tests have become the most promising type of tests for SARS-CoV-2, due to 
short waiting time to obtain the result, simple method of smear collection, and its 
affordability compared to other types of tests. The size of the market, not only 
institutional (clinics, HEDs, offices, airports, etc.), but also commercial (tests 
performed on individual orders of private persons and companies) ensured business 
success. Hence, many companies have taken up the challenge of developing a rapid 
antigen test. 
 
The decision to start work on the development of a diagnostic test for the detection 
of COVID-19 required the company to introduce changes on many levels of the its 
operation, due to time constraints resulting from the "window of opportunity". The 
imperative of shortening the time needed to develop the SARS-CoV-2 virus test 
resulted in the need to implement improvements in the company. 
 
The company’s objective was to have a finished product – a COVID-19 ready for 
marketing authorization in June 2020, i.e., 5 months after the commencement of 
work. The sales was estimated at 70 thousand items by the end of 2020. In order to 
achieve this goal, changes were introduced, both in the research and development 
(design) and production areas. 
 
4.1 Introducing Improvements in the Research and Development (Design) Area 
 
The company has divided the research and development activities into three phases, 
similar to ones used in the case of the influenza test: 
 
• R&D Phase I - antigen selection and bioreceptor selection, 
• R&D Phase II - initial work on the test and integration of all test elements 
(chemical, electronic, IT and biotechnological), 
• R&D Phase III - smear testing. 
 
The company benefited from the experience gained while working on the influenza 
virus test. Assuming that the SARS-Cov-2 virus is similar to the influenza virus, the 
time needed for the commercialization process and the necessary resources were 
estimated. This is shown in Figure 2. 
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Figure 2. Diagram of the research work division. 
 
Source: Own study. 
 
At the beginning of the development process, improvements were implemented in 
particular research and development phases, as shown in Figure 3. 
 
Figure 3. Improvements introduced in respective phases of the research. 
 
Source: Own study. 
 
Thanks to the implemented improvements, the duration of the research stage was 
significantly reduced (to 4 months), as shown in Figure 4. 
  
Figure 4. Time saved thanks to the introduction of improvements in the R&D area. 
 
Source: Own study. 
 
The implemented improvements were associated with a number of risks that the 
company had to accept in order to optimize the entire test development process and 
maintain the assumed time limits. 




In Phase I, the possible risks were associated with the following activities: 
 
• incorrect antigen choice – inability to find an appropriate bioreceptor, 
• missing results of analyses – risk of selecting non-specific bioreceptors, i.e., 
selecting an inappropriate biofilm layer, causing non-specificity or low 
sensitivity of the test. 
 
The following potential risks were identified in Phase II: 
 
• incorrect selection of the diagnostic platform – the company used the existing 
influenza diagnostic platform (owned by the company), 
• inability to test various reaction conditions, with the risk of selecting non-
specific conditions and, in consequence, test failure. 
 
In phase III, the possible risk was related to the lack of control over the obtained 
samples, which could make the verification of the test effectiveness difficult or 
significantly prolonged. The company estimated the possibility of occurrence of 
risks in the R&D area as follows in Table 1. 
 
Table 1. Estimation of the risks in R&D area. 
Event Probability of occurrence (%) 
incorrect antigen selection 10 
non-specific bioreceptor selection 50 
incorrect diagnostic platform 
selection 
10 
non-specific conditions selection 60 
Source: Own study. 
 
The company identified the greatest risks in the area of (1) non-specific bioreceptor 
selection, i.e. the selection of an inadequate biofilm layer at the earlier stages of 
research and development resulting in non-specificity or low sensitivity of the test, 
and (2) non-specific conditions selection, i.e. the selection of inappropriate 
conditions of the detection reaction (e.g., buffer, pH, concentration of individual 
components, reaction time). Under poorly selected conditions, the detection reaction 
is not visible or non-specific interactions occur, which negatively affects the 
sensitivity and specificity of the test.  
 
4.2 Improvements in the Production Area 
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Due to the adopted timeframe, the company was conducting the research and 
production activities simultaneously. The interdependence between the R&D and 
production activities is presented in Figure 5. 
 
Figure 5. The interdependence between the R&D and production activities. 
 
Source: Own study. 
 
The link between the second R&D phase and the first production phase consisted in 
the commencement of production line testing in R&D Phase II, resulting in a 
significant acceleration of the process. The production line testing consisted in 
small-scale production with the selection of various parameters followed by the 
verification of the correctness of the introduced modifications, the stability over time 
and reactivity to positive and negative samples. In addition, the company had to 
accept the risk of occurrence of errors in the third R&D phase and the related 
consequences in the form of the need to go back with the entire process, both the 
research phase (return to phase I and II, respectively) and production phase (return to 
phase I and II, respectively). The improvements that the company introduced in the 
production area are shown in Figure 6. 
 
Thanks to the introduced improvements, the Company shortened the overall research 
and production process to 8 months. After 5 months, the product was ready for 
registration at the Polish Office for Registration of Medical Devices and Biocidal 
Products, and it took the company 3 more months to scale up production, i.e., 
increase the number of manufactured tests. 
 
 




Figure 6. Improvements introduced in respective phases of production 
 
Source: Own study. 
 
The process of implementing fast production was burdened with many risks. The 
most serious risk was related to the potential necessity of modifying the entire 
process, if it had ultimately turned out that some element of the final product had not 
functioned properly. Another risk was related to the possible occurrence of "waste 
products", i.e. tests that did not pass the quality control due to damage (e.g., 
scratches) that would prevent proper bioreceptor attachment and to the instability of 
the final product. The company estimated the possibility of occurrence of risks in the 
production area (Table 2). 
 
Table 2. Estimation of the risks in the production area 
Event Probability of 
occurrence (%) 
Waste products 100 
Instability of the finished product 30 
Problems production scale up 50 
Occurrence of unexpected reaction/processes in 
the course of production 
40 
Lack of process repeatability 30 
Source: Own study. 
 
4.3 Financial Costs of Implementing Improvements 
 
The imperative to shorten the time of development has significant financial 
consequences. When conducting works simultaneously, working intuitively, and 
starting activities based on incomplete research results, one should take into account 
the increase in the costs of individual phases, which directly affects the profitability 
of the entire process. The most risky and costly changes introduced by the company 
in the process of the COVID-19 test commercialization included: 
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• focus on production rescaling, which resulted in the occurrence of a significant 
percentage of "waste products", i.e. tests that did not pass quality control, 
• time optimization when assessing the stability of the finished product - the 
impact of the production process on product stability was not fully verified, 
• skipping checkpoints (milestones/verifiers), 
• overtime, which significantly contributed to the increase in the value of payroll 
(by 50% on average). 
 
The consequences of the introduced improvements in terms of the functional test 
percentage are shown in Figure 7. 
 
Figure 7. The correct function funnel for the developed SARS-CoV-2 test. 
 
Source: Own study. 
 
At the production stage, 30% of the tests were not saleable due to poor product 
quality in terms of accuracy. Of the properly functioning products, 75% turned out to 
be unstable, which also made them unfit for sale. Stable, full value tests were those 
that had not been damaged and had passed positive verification in terms of 
measurement repeatability. 
 
In the process of risk assessment, the company accurately predicted the occurrence 
of "waste products", while maintaining the stability of products turned out to be the 
biggest problem. Due to the lack of full verification of the impact of the production 
process on the product stability, only 17.5% of the tests turned out to be full-value, 
stable and saleable products. Undoubtedly, the lack of product stability influenced 
the entire commercialization process of the COVID-19 tests. 
 
The imperative of reducing the time to develop the COVID-19 test certainly left its 
mark on the entire commercialization process. Significant acceleration of the 
research and production process resulted in the lack of full commercialization 




understood as the introduction of the product onto the market and execution of sales 
plans. This is illustrated by the following data: 
 
• 17.5% – full value, stable tests with repeatable parameters 
• 1200 – the number of tests sold (against the assumed 70,000 items) 
• disproportionately high costs incurred in the test development and production. 
 
Finally, due to the problems related to instability of the product, the company 
decided to take the production process back to the product scaling stage. Taught by 
experience, the company allocated more time to repeat this process and plans to 
introduce the product to the market in over 5 months. 
 
5. Discussion  
 
The company's decision to accelerate the work on the development of the COVID-
19 test should be considered in terms of time, costs and risk taken. However, to 
make the analysis and evaluation more complete, Table 3 summarizes the effects of 
commercialization of the SARS-CoV-2 test and the influenza test. The influenza 
virus test is the company's flagship product, successfully commercialized. 
 
Table 3. Comparison of the key features of the influenza test and the COVID-19 test 




The costs of production (in arbitrary cost units) include 
R&D and production areas 
2 1 
Development time (R&D and production) 36 
months 
8 months 
Number of employees involved 30 30 
Full commercialization yes no 
Source: Own study. 
 
Due to the market conditions (raging pandemic and the emphasis on developing the 
test quickly), as well as the unknown nature of the SARS-CoV-2 virus, the company 
did not see the possibility of determining realistic and rational levels of checkpoints, 
and then imposing them as a condition for progressing with further activities. Up to a 
certain point in the course of work on the SARS-CoV-2 test, it seemed that the 
experience gained during the commercialization of the previous product, the 
influenza test, was working.  
 
However, more or less in the middle of the R&D works, it turned out that there were 
more and more problems with the sensitivity and repeatability of the test, a large 
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percentage of invalid tests, and sales after commercialization, which was much 
lower than planned. Therefore, despite the implementation of the respective phases 
of the research and production processes in accordance with the schedule, less than 
18% share of full value products warrants negative assessment of abandoning the 
sequential method of product implementation and strict control of subsequent stages 
of the research process. Greater focus on research results, control at the completion 
of milestones phases, and maintaining a time buffer between phases would help 
avoid problems that occurred at the later stages of the process. Each research process 
requires concentration and diligence. Disregarding these requirements results in the 
accumulation of errors and, consequently, accepting a significant probability that the 
ultimate result will not be consistent with the assumptions. 
 
Another important issue is that the management mistakenly assumed that the 
research process established for SARS-CoV-2 would be essentially analogous to that 
for the influenza virus. This assumption was based on the assignment of both 
pathogens to the virus family. The analysis shows that the new virus turned out to be 
much more difficult at the detection stage, more unpredictable and, consequently, 
posed a much greater challenge for researchers in the first R&D phase. SARS-CoV-
2 is a new pathogen, the research on which has began relatively recently - it will take 
time and a series of in-depth studies to gain more knowledge about its testing. 
Adding a very innovative and therefore also complicated technology (electronic 
layer) that was used for the SARS-CoV-2 virus, it can be concluded that following 
the research pathway used in the case of the previously developed influenza test too 
closely turned out to be illusionary and also contributed to deficiencies in the 
stability of the SARS-CoV-2 test. As a consequence, the company had to go back to 
the first R&D phase and gave itself another month to refine the test. 
 
When analyzing the temporal aspect of the COVID-19 test commercialization, it 
should be stated that, thanks to the introduced improvements, the company 
registered the product with The Office for the Registration of Medicinal Products, 
Medical Devices and Biocidal Products at the scheduled time. So, formally, it 
achieved its main objective. However, if we take into account the low percentage of 
stable tests, it turns out that the objective of accelerating the work was not really 
achieved, because it took months to refine the test. As a result, sales levels were not 
achieved in line with the adopted schedule. 
 
In terms of costs, the Company incurred huge expenses due to the pace of the 
process: a very large percentage of "waste products" (30%) at the quality control 
stage and a huge percentage of defective products due to their instability (70%). This 
directly influenced the sales of products - out of the assumed 70 thousand items, the 
Company sold 1,200 items of the product (1.71% of the plan). 
 
Secondly, the nominal cost of production of the influenza test is twice as high as 
COVID-19 test, mainly due to the much longer research and development stage (36 
months vs. 8 months), which generated much higher salary costs. The COVID-19 




test was based on the knowledge previously acquired during the work on the 
influenza virus test and the process of its development took 8 months (R&D works 
plus the production scaling process). Nevertheless, on the basis of the monthly costs, 
the COVID-19 test development turned out to be much more expensive compared to 
the commercialization of the flu test. The average monthly cost for the SARS-CoV-2 
test was 1/8 of the arbitrary cost unit, while for the flu test it was 1/18 of the 
arbitrary cost unit, which means twice higher monthly costs. Thus, the company 
incurred over-proportional expenses to commercialize only a partially reproducible 
test, focusing (prioritizing) on shortening the time to commercialization. 
 
The company generally correctly identified the catalogue of risks related to the 
launch of the new test onto the market, noticing the dangers at various stages of the 
research and production processes (see Tables 1 and 2). However, at the beginning 
of the new project, the risk of achieving sufficient stability of the SARS-CoV-2 test 
was underestimated, being set at 30%. Meanwhile, this risk materialized in 75% of 
the produced tests. From a biological point of view, the reproducibility of the 
bioreceptor response is difficult to achieve, as seen in the previous work on the 
influenza test. Here, too, the adopted assumption of the similarity between the 
detection of influenza virus and SARS-CoV-2 as well as the biosensor response has 
left its mark. 
 
The high level of risk associated with innovative projects became even higher due to 
the acceleration of research works and manifested itself in the form of a non-fully 
functional finished product, resulting in the need to continue work on a fully 
reproducible test for SARS-CoV-2. Conducting innovative activities in the 
circumstances of a perceived "window of opportunity” fully revealed the typical 
trade-offs: 
 
• too early release of the product vs unused opportunities 
• time-to-market vs development cost 
• time-to-market vs product features. 
 
Thanks to the mobilization of the research and production personnel, organizational 
improvements, the use of previous experience from developing the influenza test, the 
involvement of significant financial capital, and above all, the conviction of the 
company's management that the window of opportunity related to the launch of 
serial production of the SARS-CoV-2 test would close quickly - the time of 
development of the COVID-19 test was shortened to 8 months. The time to develop 
the company’s second test was reduced significantly – by 77%, with the same 
structure and size of R&D staff. At the same time, the average monthly cost of 
developing and launching the SARS-CoV-2 test was twice (225%) the cost of 
developing the influenza test. Thus, the time-to-market vs development cost 
dilemma in the analyzed case indicates a relatively small increase in time benefits 
compared to expenses. 
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The results for the next trade-off, time-to-market vs. product features, are similarly 
unfavorable. Due to the lack of repeatability (18% share of stable tests in overall 
production), it should be concluded that the acceleration of commercialization had a 
negative impact on the features of the finished product. Despite the official 
registration of the COVID-19 test with the competent authority, the company has 
been continuing work on the test in order to scale up the production. 
 
Seizing the window of opportunity initially appeared to be the main motivator for 
making the efforts to accelerate R&D activities. The company's management 
correctly identified the growing competition in the scope of development and 
subsequent production of SARS-CoV-2 tests. The time of launching the test on the 
market is associated with gaining a competitive advantage on the first mover basis. 
However, the desire to "fit into" the window of opportunity and overtake rivals 
overshadowed the critical assessment of test preparation for serial production. As a 
result, the company has to keep refining the product in the coming months, and 
during this time more tests are appearing on the market (FindDX, 2020).  
 
The company commercialized too quickly (although the benefit of the formal 
registration of the SARS-CoV-2 test should be noted) and at this stage it is not 
obtaining any market or financial benefits, and even has to provide extra funds on 
additional R&D works. Thus, the analyzed case shows that there is indeed a strong 
complementary effect between starting the production of a new product too quickly 
and too slowly. If it is not possible to control the entire innovation process, this 
trade-off translates into no benefits, signaling that a better solution could be to enter 





From a cognitive point of view, the analyzed commercialization of the SARS-CoV-2 
test is an interesting study of the use of the emerging window of opportunity, if there 
is an objective (forced by social and economic needs) need to accelerate work on a 
new product, and on the other hand, if there is a previously proven potential for 
effective implementation of innovation. In such circumstances, the mobilization of 
human and financial resources takes place, organizational and management 
improvements are applied, and the managers conduct the project with great 
determination, striving for the fastest possible market success. However, in line with 
theoretical assumptions, when the window of opportunity is short, the enterprises 
unavoidably face the trade-offs associated with the optimization of time, cost, risk 
and the moment of product launch (Bayus, 1997). 
 
As the analyzed case study shows, the benefits of quick product development and 
serial production launch may be disproportionately small in such conditions 
compared to the expected market effects (market share, building brand awareness, 
competitive position), financial (profits, costs) and the necessity to refine the product 




functionality. Despite the time pressure, it is advisable to follow the main principles 
of conducting the research process, in particular, defining milestones in advance, 
exercising critical approach to formulating assumptions, taking care of good 
communication between R&D discipline teams, making at least a preliminary trade-
off calculation. 
 
There is an opinion expressed in the literature on the subject that quality can be 
sacrificed at the altar of accelerating R&D work on biotechnological products 
(Linton and Xu, 2021). However, as the analyzed case shows, there is a minimum 
product functionality below which a positive commercialization effect cannot be 
expected. Only after exceeding this limit can the functions of the product be 
modified. In the case of a medical test - the quality of the device is primarily related 
to the repeatability of measurement, which the company did not manage to ensure to 
a sufficient degree. The above conclusions are consistent with the Minimum Viable 
Product concept and suggest its wider adoption in the biotechnology industry (Still, 
2017). 
 
The case study presented here indicates that despite the feeling of strong (and 
objectively present) urgency to launch serial production of the SARS-CoV-2 test, it 
is necessary to precisely define the features/parameters of the finished product and to 
control the behavior of the above elements throughout the commercialization 
process. The problem is that it must be done at the very beginning of product 
development process, largely without full awareness of the effects that can be 
achieved. However, as this example shows, without defining the functionality more 
precisely, decision-makers may focus on a single factor (time to commercialization, 
to the detriment of other aspects (cost, features). And this, in turn, ultimately led to 
the need to improve the COVID-19 test, thus eliminating the chances of 
commercializing the product within the window of opportunity and at the same time 
generating a considerable cost increase. Further investments necessary in the process 
of increasing the stability of the test and the growing number of competitors 
successfully commercializing their SARS-CoV-2 tests will most likely delay 
successful commercialization. 
 
In the end of this paper, it is worth mentioning the limitations that the authors 
encountered in the research process. The basic limitation is related to the adopted 
method of case study analysis. Although this decision was made consciously 
regarding the nature of the analyzed phenomena (grasping the dynamic and 
situational innovation processes in statu nascendi), it translates directly into the 
limited possibility of generalizing the conclusions. 
 
Another limitation concerns the local context of the conducted research. The 
analyzed company is located in Poland, and the office registering medical products 
operates in accordance with the Polish law. This raises issues of specific 
organizational culture and organizational behavior. 
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The research that is worth undertaking in the future is to conduct studies on the 
trade-off effects occurring in the process of commercialization of biomedical 
products using a wider sample. Another promising direction of research is 
conducting longitudinal studies analyzing the company in terms of the degree of 
improvement of innovation processes, increase in the substantive and management 
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